Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F James

Showing results (991-1000 of 1,011) with videos related to

Pageof 102
Sort By:
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Blood Pressure|December 14, 1999
Study on COgnition and Prognosis in the Elderly (SCOPE)L Hansson, H Lithell, I Skoog, et al.
Blood Pressure|June 16, 2000
Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristicsL Hansson, H Lithell, I Skoog, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Cell Reports|April 12, 2018
Environmental Enrichment and Social Isolation Mediate Neuroplasticity of Medium Spiny Neurons through the GSK3 PathwayFederico Scala, Miroslav N Nenov, Elizabeth J Crofton, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|September 8, 2021
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel diseaseJoerg Ermann, Mederbek Matmusaev, Emma K Haley, et al.
Journal of Medicinal Chemistry|July 17, 2007
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetrationEdward K Dziadulewicz, Stuart J Bevan, Christopher T Brain, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
The Lancet. Haematology|May 22, 2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validationsJacob D Soumerai, Ai Ni, Mohamed Darif, et al.
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Pageof 102

Showing results (991-1000 of 1,011) with videos related to

Sort By:
Pageof 102
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Blood Pressure|December 14, 1999
Study on COgnition and Prognosis in the Elderly (SCOPE)L Hansson, H Lithell, I Skoog, et al.
Blood Pressure|June 16, 2000
Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristicsL Hansson, H Lithell, I Skoog, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Cell Reports|April 12, 2018
Environmental Enrichment and Social Isolation Mediate Neuroplasticity of Medium Spiny Neurons through the GSK3 PathwayFederico Scala, Miroslav N Nenov, Elizabeth J Crofton, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|September 8, 2021
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel diseaseJoerg Ermann, Mederbek Matmusaev, Emma K Haley, et al.
Journal of Medicinal Chemistry|July 17, 2007
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetrationEdward K Dziadulewicz, Stuart J Bevan, Christopher T Brain, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
The Lancet. Haematology|May 22, 2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validationsJacob D Soumerai, Ai Ni, Mohamed Darif, et al.
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Pageof 102